In alignment with MDM2, NCL is frequently overexpressed in various cancer types, and it exhibits a dynamic shuttling mechanism between the nucleus, cytoplasm, and cell surface, as well as serving as a membrane-anchored receptor in both tumor cells and endothelial cells of angiogenic blood vessels [191–193]. Here, MDM2 is linked to cancer.